Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway

Paclitaxel (PTX) is widely used in the front-line chemotherapy for gastric cancer (GC), but resistance limits its use. Due to the lack of proper models, mechanisms underlying PTX resistance in GC were not well studied. Using established PTX-resistant GC cell sublines HGC-27R, we for the first time i...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Dongshao, Lin, Xiaoting, Zhang, Cheng, Liu, Zhentao, Chen, Zuhua, Li, Zhongwu, Wang, Jingyuan, Li, Beifang, Hu, Yanting, Dong, Bin, Shen, Lin, Ji, Jiafu, Gao, Jing, Zhang, Xiaotian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833539/
https://www.ncbi.nlm.nih.gov/pubmed/29374144
http://dx.doi.org/10.1038/s41419-017-0132-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833539/
https://www.ncbi.nlm.nih.gov/pubmed/29374144
http://dx.doi.org/10.1038/s41419-017-0132-2

Ejemplares similares